Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Ionis Pharmaceutical (IONS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,685,536
  • Shares Outstanding, K 124,800
  • Annual Sales, $ 346,620 K
  • Annual Income, $ -86,560 K
  • 36-Month Beta 2.85
  • Price/Sales 19.21
  • Price/Cash Flow N/A
  • Price/Book 16.62

Price Performance

See More
Period Period Low Period High Performance
1-Month
50.87 +1.36%
on 12/06/17
57.92 -10.98%
on 12/04/17
-1.97 (-3.68%)
since 11/14/17
3-Month
47.75 +7.98%
on 09/29/17
65.51 -21.29%
on 10/20/17
-6.81 (-11.67%)
since 09/14/17
52-Week
37.26 +38.38%
on 04/06/17
65.51 -21.29%
on 10/20/17
+4.24 (+8.96%)
since 12/14/16

Most Recent Stories

More News
Ionis Pharmaceuticals Licenses IONIS-HTT Rx to Partner Following Successful Phase 1/2a Study in Patients with Huntington's Disease

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that Roche has exercised its option to license IONIS-HTTRx following the completion of a Phase 1/2a randomized, placebo-controlled, dose escalation...

IONS : 51.56 (-3.75%)
Akcea to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference

Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid...

AKCA : 19.15 (-0.26%)
IONS : 51.56 (-3.75%)
Ionis Pharmaceuticals to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the BMO Capital Markets 2017 Prescriptions for Success...

IONS : 51.56 (-3.75%)
Report: Developing Opportunities within Ionis Pharmaceuticals, Alder BioPharmaceuticals, Robert Half International, Ashford Hospitality Trust, Southwest Gas, and Stoneridge -- Future Expectations, Projections Moving into 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ionis Pharmaceuticals, Inc....

RHI : 54.22 (-0.24%)
SWX : 79.40 (-1.40%)
ALDR : 10.70 (-3.17%)
IONS : 51.56 (-3.75%)
SRI : 22.72 (+0.26%)
AHT : 6.75 (-1.17%)
Today's Research Reports on Stocks to Watch: Ionis Pharmaceuticals and GW Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / December 5, 2017 / Both Ionis Pharmaceuticals and GW Pharmaceuticals saw losses on Monday. GW Pharmaceuticals closed down a little over 6% despite announcing fourth quarter...

IONS : 51.56 (-3.75%)
GWPH : 130.82 (+5.52%)
Ionis Pharmaceuticals Licenses Second Orally Delivered Antisense Drug to Janssen

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it has licensed a second orally delivered Generation 2.5 antisense drug to Janssen Biotech, Inc. (Janssen) for which Ionis earned $5 million....

IONS : 51.56 (-3.75%)
Akcea and Ionis Announce Acceptance of Marketing Applications in U.S., EU and Canada for Volanesorsen for the Treatment of FCS

Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases...

AKCA : 19.15 (-0.26%)
IONS : 51.56 (-3.75%)
Akcea Initiates AKCEA-ANGPTL3-LRx Phase 2 Program in Patients with Rare Hyperlipidemias

Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases...

AKCA : 19.15 (-0.26%)
IONS : 51.56 (-3.75%)
New Research: Key Drivers of Growth for Williams-Sonoma, U.S. Silica, RH, Ionis, Burlington, and McCormick & Company - Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Williams-Sonoma, Inc. (NYSE:WSM),...

WSM : 50.39 (-3.65%)
SLCA : 34.45 (+1.59%)
BURL : 109.32 (-0.92%)
MKC : 100.24 (-0.71%)
RH : 98.65 (-2.17%)
IONS : 51.56 (-3.75%)
Ionis Licenses Novel Antisense Drug for the Treatment of Centronuclear Myopathy to Dynacure

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and Dynacure announced today that Dynacure has licensed IONIS-DNM2-2.5Rx (Dyn101), a Generation 2.5 antisense drug targeting dynamin 2 for the treatment of centronuclear...

IONS : 51.56 (-3.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

See More

Business Summary

Ionis Pharmaceuticals, Inc. is a RNA-targeted drug discovery and development company which focuses on developing drugs for severe and rare diseases. Ionis Pharmaceuticals, Inc., formerly known as Isis Pharmaceuticals, Inc., is headquartered in Carlsbad, California.

See More

Key Turning Points

2nd Resistance Point 54.67
1st Resistance Point 53.11
Last Price 51.56
1st Support Level 50.69
2nd Support Level 49.83

See More

52-Week High 65.51
Fibonacci 61.8% 54.72
Last Price 51.56
Fibonacci 50% 51.39
Fibonacci 38.2% 48.05
52-Week Low 37.26

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.